Ecleralimab Biosimilar - Research Grade

Human

TSLP

>1mg/ml

Fab - G1 - lambda2

CHO Cells

Tezepelumab Biosimilar - Research Grade (ICH5213), Bosakitug Biosimilar - Research Grade (ICH5410), Ocankitug Biosimilar - Research Grade (ICH5720)

https://www.imgt.org/mAb-DB/

ICH3002

Q969D9

Blue ice

This product is a research-grade, non-therapeutic recombinant analog of the anti-TSLP antibody fragment ecleralimab, supplied for research use only and not for human or veterinary use. It is an unconjugated Fab (human IgG1 heavy-chain fragment paired with a lambda2 light chain) engineered to bind human thymic stromal lymphopoietin (TSLP; UniProt Q969D9), the same target as the originator molecule. Being a monovalent Fab it lacks an Fc region and any effector function, which makes it a clean reagent for studying antigen recognition in isolation from Fc-mediated activity. It is useful as a target-blocking tool for in-vitro neutralization assays, as a positive or reference control in binding and epitope studies, for benchmarking new anti-TSLP binders, and in preclinical development workflows. The material is offered as a low-endotoxin preparation (research grade less than 1 EU/mg; ultra-low grade less than 0.5 EU/mg available) and can be produced at bulk milligram-to-gram scale to support screening, formulation, and assay-development programs. Thymic stromal lymphopoietin (TSLP) is an IL-7-like epithelial-derived cytokine released by barrier tissues such as airway and skin epithelium in response to allergens, viruses, and other insults. It signals through a heterodimeric receptor composed of the TSLP receptor chain (TSLPR/CRLF2) and the IL-7 receptor alpha chain (IL7R), activating JAK1/JAK2 and STAT5 signaling. TSLP acts as an upstream "alarmin" that drives type 2 (Th2) inflammation: it conditions dendritic cells, activates group 2 innate lymphoid cells, and promotes production of IL-4, IL-5, and IL-13, along with eosinophil recruitment and IgE responses. Because it sits at the top of the allergic-inflammatory cascade, TSLP is a central therapeutic target in asthma and other type 2 inflammatory diseases, and neutralizing soluble TSLP prevents receptor engagement and downstream signaling.

Thymic stromal lymphopoietin

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Ecleralimab biosimilar available in bulk or gram quantities?

A: Yes — the Ecleralimab biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is this research-grade Ecleralimab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Ecleralimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Ecleralimab that binds TSLP.